Book a Meeting

E3 Ligase and Target Proteins

PROTAC®s degrade the disease-causing proteins by hijacking the ubiquitin-proteasome system (UPS). Unlike traditional small-molecule inhibitors, PROTAC®s provide a better and more efficient strategy. During the discovery process of an efficient PROTAC® molecule, multiple parameters and details need to be optimized and designed, such as the affinity of PROTAC® molecules to target proteins and to the E3 ligase proteins. Besides, although there are nearly 600 ligases identified in the human genome, many of them remain relatively uncharacterized. To reveal their substrates, in vitro high-throughput screening with purified E3 ligase is an approach. To make it possibly easier to fulfill the optimization and the characterization, Creative Biolabs produces several proteins including E3 ligases and target proteins as products.

Our services are For Research Use Only. We do not provide direct services for patients.
Type: Target protein
Size: 0.1 mg
a.a:
Type: E3 ligase protein
Size: 0.02 mg
a.a:

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    USA
  • Address:
  • Tel:
  • Fax:
  • Email:
    UK
  • Address:
  • Tel:
  • Email:
    Germany
  • Address:
  • Tel:
  • Email:
Social Media
PROTAC® is a registered trademark owned by Arvinas Operations, Inc.
Copyright © 2024 Creative Biolabs. All Rights Reserved.